- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07449702
Een open-label-extensiestudie van ORKA-001 bij deelnemers met plaque psoriasis
Een open-label vervolgstudie om de langetermijnveiligheid, verdraagbaarheid en werkzaamheid van ORKA-001 te evalueren bij deelnemers met matige tot ernstige plaque psoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Studie Overzicht
Gedetailleerde beschrijving
This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Oruka Clinical Trials Information
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
Studie Locaties
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3S9
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Edmonton, Alberta, Canada, T6G 1C3
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Surrey, British Columbia, Canada, V3V 0C6
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B IG9
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Ontario
-
Ajax, Ontario, Canada, L1S7K8
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
London, Ontario, Canada, N6H 5L5
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Markham, Ontario, Canada, L3P 1X3
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Peterborough, Ontario, Canada, K9J 5K2
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Toronto, Ontario, Canada, M4W 2N4
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Waterloo, Ontario, Canada, N2J 1C4
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Quebec
-
Montreal, Quebec, Canada, H2X2V1
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Québec, Quebec, Canada, G1V4X7
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85032
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Arkansas
-
North Little Rock, Arkansas, Verenigde Staten, 72117
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
California
-
Fountain Valley, California, Verenigde Staten, 92708
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Los Angeles, California, Verenigde Staten, 90045
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
San Diego, California, Verenigde Staten, 92123
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Santa Ana, California, Verenigde Staten, 92701
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Santa Monica, California, Verenigde Staten, 90403
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Connecticut
-
Cromwell, Connecticut, Verenigde Staten, 06416
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33126
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Illinois
-
Rolling Meadows, Illinois, Verenigde Staten, 60008
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Indiana
-
Plainfield, Indiana, Verenigde Staten, 46168
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Kentucky
-
Bowling Green, Kentucky, Verenigde Staten, 42104
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- E-mail: clinicaltrials@orukatx.com
-
-
Maryland
-
Rockville, Maryland, Verenigde Staten, 20850
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48202
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
New York
-
New York, New York, Verenigde Staten, 10023
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
New York, New York, Verenigde Staten, 10029
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Mason, Ohio, Verenigde Staten, 45040
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97201
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Portland, Oregon, Verenigde Staten, 97210
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Texas
-
Frisco, Texas, Verenigde Staten, 75033
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Houston, Texas, Verenigde Staten, 77004
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
Webster, Texas, Verenigde Staten, 77598
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Therapeutics Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Oruka Therapeutics Investigative Site
-
Contact:
- Oruka Investigative Site
- Telefoonnummer: 781-560-0299
- E-mail: clinicaltrials@orukatx.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Exclusion Criteria:
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: ORKA-001 Once Yearly (High Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimenteel: ORKA-001 Once Yearly (Low Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Experimenteel: ORKA-001 Twice Yearly
Participants will receive ORKA-001 every 6 months per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Geen tussenkomst: No Drug
Participants will receive no drug until protocol defined PASI response criterion is met. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Tijdsspanne: Day 1 through Week 144
|
Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms. |
Day 1 through Week 144
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tijdsspanne: Time Frame: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Time Frame: Day 1 through Week 96
|
|
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Tijdsspanne: Day 1 through Week 96
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Tijdsspanne: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Tijdsspanne: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
PASI Score Over Time
Tijdsspanne: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
IGA Score Over Time
Tijdsspanne: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- ORKA-001-113
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .